Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse

BMC Gastroenterology

Table 3 Multivariate analysis of prognostic factors predicting overall recurrence-free survival according to cancer location

	Colorectal cancer (n = 277)		Rectal cancer (n = 104)		Colon cancer (n = 173)
Variables	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
miR-21 expression (low vs. high)	2.24 (1.25-4.02)	0.007	1.65 (0.65-4.16)	0.295	2.45 (1.05-5.72)	0.038
Age (<65 years vs. ≥65 years)	1.03 (0.56-1.89)	0.924	0.27 (0.10-0.70)	0.007	2.48 (1.00-6.12)	0.049
Tumor type (non-mucinous vs. mucinous)	0.61 (0.13-2.97)	0.539	0.62 (0.03-11.50)	0.751	1.03 (0.13-8.48)	0.976
Differentiation (well or moderately vs. poorly)	2.18 (0.83-5.71)	0.114	2.60 (0.55-12.21)	0.225	1.56 (0.41-5.94)	0.513
pT (T3 vs. T4a)	1.97 (1.01-3.83)	0.046	2.26 (0.75-6.79)	0.145	2.27 (0.86-5.97)	0.098
Lymph node metastasis (absent vs. present)	4.55 (2.23-9.29)	0.00003	11.75 (3.33-41.48)	0.0001	3.02 (1.22-7.47)	0.017
CEA (<5 ng/dL vs. ≥5 ng/dL)	2.63 (1.46-4.74)	0.001	3.32 (1.39-7.51)	0.006	2.65 (1.13-6.21)	0.025
Adjuvant therapy (no vs. yes)	2.48 (0.32-19.32)	0.386	NA	NA	2.15 (0.26-18.08)	0.431

HR, hazard ratio; CI, confidence interval; NA, not available. Multivariate analysis is adjusted for age (<65 years vs. ≥65 years), tumor type (non-mucinous vs. mucinous), differentiation (well or moderately vs. poorly), pT (T3 vs. T4a), lymph node metastasis (absent vs. present), CEA (<5 ng/dL vs. ≥5 ng/dL) and adjuvant therapy (no vs. yes).

ISSN: 1471-230X